Startseite>>Analytical Standards>>AGN 193109-d7

AGN 193109-d7

Katalog-Nr.GC46817

AGN 193109-d7 ist das mit Deuterium markierte AGN 193109. AGN 193109 ist ein Retinoidanalogon und wirkt als spezifischer und hochwirksamer Antagonist von RetinsÄurerezeptoren (RARs) mit Kds von 2 nM, 2 nM und 3 nM fÜr RARα , RARβ bzw. RARγ.

Products are for research use only. Not for human use. We do not sell to patients.

AGN 193109-d7 Chemische Struktur

Cas No.: 1216429-25-2

Größe Preis Lagerbestand Menge
1 mg
556,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

AGN 193109-d7 is intended for use as an internal standard for the quantification of AGN 193109 by GC- or LC-MS. AGN 193109 is an antagonist of retinoic acid receptors (RARs).1 AGN 193109 decreases expression of cytokeratin K5-8, 13, 14, 16, 17, and 19 genes, markers of retinoid action in ECE16-1 cells, when co-administered with TTNPB but not when used alone. In vivo, AGN 193109 induces cleft palate or frontonasal dysplasia and eye malformations in fetuses of pregnant mice following a single oral dose of 1 mg/kg.2

1.Agarwal, C., Chandraratna, A.S., Johnson, A.L., et al.AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cellsJ. Biol. Chem.271(21)12209-12212(1996) 2.Kochhar, D.M., Jiang, H., Penner, J.D., et al.The use of a retinoid receptor antagonist in a new model to study vitamin A-dependent developmental eventsInt. J. Dev. Biol.42(4)601-608(1998)

Bewertungen

Review for AGN 193109-d7

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AGN 193109-d7

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.